| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/10/2003 | US20030129211 Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides |
| 07/10/2003 | US20030129209 Topical application of cetirizine and loratadine |
| 07/10/2003 | US20030129205 Inducing presensitization of immune system towards an immunogen carrying lymphocytes epitope homologous to allergen; immunosuppressants |
| 07/10/2003 | US20030129194 Conjugates for binding bone and tumor tissue; antiproliferative agents; osteoporosis |
| 07/10/2003 | US20030129191 Radiolabeled biotin and derivatives/conjugates bind hepatocyte receptors; anticancer agents; drug delivery |
| 07/10/2003 | US20030129188 Peptide mimetics; catalytic antibodies such as aldolase, beta-lactamase, esterase, or amidase; for treatment of angiogenesis, bone metabolism disorders, inflammation, or cell growth disorders |
| 07/10/2003 | US20030129186 Compositions and methods for modulating blood-brain barrier transport |
| 07/10/2003 | US20030129182 Contacting vitreous humor with beta-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase, and/or protein kinase; thimerosal-free |
| 07/10/2003 | US20030129181 Hydrolases modified by polyoxyethylene glycol for induction of high plasmatic levels of free tumor necrosis factor |
| 07/10/2003 | US20030129167 Enhanced production of blood components, blood cells and plasma without freezing |
| 07/10/2003 | US20030129156 Use of a polypeptide for treatment of pruritis in animals |
| 07/10/2003 | US20030129145 Aftersmoking; converting nicotine to cotinine; discharing in urine |
| 07/10/2003 | US20030129140 In situ infection therapy; aminoglycoside antibiotics |
| 07/10/2003 | US20030129139 Drug delivery; lightweight hollow spheres; spray drying |
| 07/10/2003 | US20030129137 Stable microbubble suspensions as enhancement agents for ultrasound echography |
| 07/10/2003 | US20030129132 IL-13 receptor specific chimeric proteins & uses thereof |
| 07/10/2003 | US20030129130 Drug delivery; microparticles immobilized on polymer surface |
| 07/10/2003 | CA2472401A1 Improved method of production of lycopene by the fermentation of selected strains of blakeslea trispora, formulations and uses of the lycopene obtained |
| 07/10/2003 | CA2472124A1 Amphiphilic compounds for pharmaceutical or cosmetic use |
| 07/10/2003 | CA2471903A1 Micronized pharmaceutical or nutraceutical powder with immediate release |
| 07/10/2003 | CA2471645A1 Immunoconjugates useful for treatment of tumours |
| 07/10/2003 | CA2471300A1 Composition comprising dextrinsulfate for the treatment of sexual transmitted diseases (std) |
| 07/10/2003 | CA2470511A1 Liquid composition of factor vii polypeptides |
| 07/10/2003 | CA2470367A1 Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atherosclerosis |
| 07/10/2003 | CA2470313A1 Liquid composition of modified factor vii polypeptides |
| 07/10/2003 | CA2469946A1 Dendritic poly (amino acid) carriers and methods of use |
| 07/10/2003 | CA2468619A1 Adiponectin fragments and conjugates |
| 07/10/2003 | CA2468081A1 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours |
| 07/10/2003 | CA2464937A1 Long chain fatty alcohol substituents in antineoplastic agents |
| 07/10/2003 | CA2463738A1 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
| 07/10/2003 | CA2462768A1 Self-assembling polymers, and materials fabricated therefrom |
| 07/09/2003 | EP1325757A1 Embolic materials |
| 07/09/2003 | EP1325752A2 Composition for transdermal and/or transmucosal administration of active compounds which ensures adequate therapeutic levels |
| 07/09/2003 | EP1325746A1 Controlled release oxycodone compositions |
| 07/09/2003 | EP1325742A1 Improved transdermal therapeutic system for the treatment of Parkinson's disease |
| 07/09/2003 | EP1325739A1 Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors |
| 07/09/2003 | EP1325736A1 Cosmetic or pharmaceutical oil-in-water emulsions comprising one or more hydrophobically modified copolymeric polyglutamic acid derivatives |
| 07/09/2003 | EP1325734A1 Process for the preparation of ozone and peroxide derivatives of fatty acids or their esters in the form of a spreadable ointment |
| 07/09/2003 | EP1325682A1 Food or pet food composition containing plant extracts for maintenance of bone health and prevention or treatment of bone diseases |
| 07/09/2003 | EP1325046A1 Zwitterionic polymers |
| 07/09/2003 | EP1325044A1 Aqueous polymer dispersion |
| 07/09/2003 | EP1325035A1 Starch |
| 07/09/2003 | EP1325034A1 Pharmaceutically acceptable starch |
| 07/09/2003 | EP1325025A1 Peptide-based gemini surfactant compounds facilitating the transfer into cells |
| 07/09/2003 | EP1325014A2 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| 07/09/2003 | EP1324782A2 Stabilized hydrogen peroxide solutions |
| 07/09/2003 | EP1324779A2 Pegylated interleukin-10 |
| 07/09/2003 | EP1324778A2 Compositions and methods for the transport of biologically active agents across cellular barriers |
| 07/09/2003 | EP1324777A1 Regioselective liquid phase pegylation |
| 07/09/2003 | EP1324776A2 Reduced-viscosity concentrated protein formulations |
| 07/09/2003 | EP1324760A1 Creatine ester pronutrient compounds and formulations |
| 07/09/2003 | EP1324755A1 Pharmaceutical solutions of modafinil compounds |
| 07/09/2003 | EP1324752A2 Delayed release pharmaceutical formulations |
| 07/09/2003 | EP1324750A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 07/09/2003 | EP1324749A2 Medicinal aerosol formulations |
| 07/09/2003 | EP1324748A1 Topical antibiotic composition for treatment of eye infection |
| 07/09/2003 | EP1173151B1 Dry, mouldable drug formulation |
| 07/09/2003 | EP1143929B1 BIODEGRADABLE pH/THERMOSENSITIVE HYDROGELS FOR SUSTAINED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS |
| 07/09/2003 | EP1028706B1 Buffered drug formulations for transdermal electrotransport delivery |
| 07/09/2003 | EP1007015B1 In situ formation of polymeric material |
| 07/09/2003 | EP0988056B1 Tissue factor methods and compositions for coagulation and tumor treatment |
| 07/09/2003 | EP0975326B1 Topical application of enzymes using a peelable film |
| 07/09/2003 | EP0964690B1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 07/09/2003 | EP0752885B1 Therapeutic inhibitor of vascular smooth muscle cells |
| 07/09/2003 | EP0190315B2 Dehydrated liposomes |
| 07/09/2003 | CN1429232A Use of azalide antibiotic compositions for treating or preventing bacterial or protozoal infection in mammals |
| 07/09/2003 | CN1429205A 磺酰胺衍生物 Sulfonamide derivatives |
| 07/09/2003 | CN1429121A Polyglutamic acid-camptothecin conjugates and methods of preparation |
| 07/09/2003 | CN1429120A Stable polymeric micelle-type drug composition and method for preparation thereof |
| 07/09/2003 | CN1429119A Method for preparation of polymeric micelle via separation of block copolymer |
| 07/09/2003 | CN1429116A Pharmaceutical composition |
| 07/09/2003 | CN1429110A Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 07/09/2003 | CN1429105A Dermal compositions containing coenzyme Q as active ingredient |
| 07/09/2003 | CN1429103A Novel process |
| 07/09/2003 | CN1429102A Hydrogel composition for transdermal drug delivery |
| 07/09/2003 | CN1429101A Stabilized aqueous suspensions for parenteral administration |
| 07/09/2003 | CN1429100A Improvements in or relating to delivery of oral drugs |
| 07/09/2003 | CN1429098A 乳化组合物 Emulsified composition |
| 07/09/2003 | CN1429097A Use of ellagic acid as anti-pollution cosmetic agent |
| 07/09/2003 | CN1429073A A gene therapy system and method using alpha-MSH and its derivatives |
| 07/09/2003 | CN1428352A Reformed monoclonal antibody for resisting immunoglobulin homoeotype |
| 07/09/2003 | CN1428144A Method for preparing mass micro-capsule |
| 07/09/2003 | CN1113912C Copolymers of carboxylic acids and multiply olefinically unsaturated carboxylic acid derivatives and their use as thickeners and dispergents |
| 07/09/2003 | CN1113670C Improved stability of prostaglandin medicine |
| 07/09/2003 | CN1113650C Drug composition of self-emulsifying agent form lipophilic compounds |
| 07/09/2003 | CN1113649C Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations |
| 07/08/2003 | US6590059 Bioerodible polyorthoesters from dioxolane-based diketene acetals |
| 07/08/2003 | US6589999 Maintains pH values compatible with ocular administration; tolerance problems even with prolonged use does not occur |
| 07/08/2003 | US6589998 Administering biocompatible polymer in solvent |
| 07/08/2003 | US6589990 Topically administering to penis to treat sexual disorder |
| 07/08/2003 | US6589988 Pharmaceutical composition with antitumor activity on the basis of carboplatin |
| 07/08/2003 | US6589973 A clear, stable novel pharmaceutical preparation of selective cyclooxygenase II inhibitors (COX 2) inhibitors in the injection form for pain and inflammation |
| 07/08/2003 | US6589955 Pediatric formulation of gatifloxacin |
| 07/08/2003 | US6589730 Methods for identifying protein-protein interactions by selective transduction |
| 07/08/2003 | US6589629 Process for fabricating patterned, functionalized particles and article formed from particles |
| 07/08/2003 | US6589576 Includes xanthan gum which improves tolerance (e.g. less gastrointestinal symptoms such as emesis, stool patterns and gas) |
| 07/08/2003 | US6589568 Therapeutic body lotion containing alkali metal hypohalite |
| 07/08/2003 | US6589566 Composition comprising theanine |
| 07/08/2003 | US6589563 Drug delivery system exhibiting permeability control |
| 07/08/2003 | US6589559 Nasally administrable compositions |